NCT00708721 · OUTCOME

Time to Progression to Acute Myeloid Leukemia (AML)

Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia · Source last updated 2017-06-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: cycles
Interval / dispersion: Not reported
Time frame: approximately 4 years

What was measured

Longest documented duration of time until progression to AML.

Analysis population: Cycles are 28 days long. Analysis assessed the longest number of cycles completed on study until progression to AML.

Groups in this outcome

All Evaluable Patients

Only nine of the eleven patients were evaluable for this outcome measure.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Evaluable Patients	9

Reported measurements

Source class 1

Values in cycles · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
All Evaluable Patients	51	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
51

denoms

counts
group Id
OG000
value
9
units
Participants

description

Longest documented duration of time until progression to AML.

groups

description
Only nine of the eleven patients were evaluable for this outcome measure.
id
OG000
title
All Evaluable Patients

param Type

NUMBER

population Description

Cycles are 28 days long. Analysis assessed the longest number of cycles completed on study until progression to AML.

reporting Status

POSTED

time Frame

approximately 4 years

title

Time to Progression to Acute Myeloid Leukemia (AML)

type

SECONDARY

unit Of Measure

cycles

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice